<DOC>
	<DOCNO>NCT01320358</DOCNO>
	<brief_summary>The main purpose exploratory trial evaluate reliability , safety usability Transplantation Sensor System Ingestible Event Marker ( IEM ) give combination ECMPS 360 mg tablet adult renal transplant recipient .</brief_summary>
	<brief_title>Reliability , Safety Usability Transplantation Sensor System Combined With MyforticÂ® Adult Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patients least 6 month posttransplantation stable clinical condition Treatment ECMPS dose 720 mg/day 1440 mg/day MMF dose between1000 mg/day 2000 mg/day , divide two equal dos 12 hour apart dose titration plan duration trial Ability independently take medication Successfully ingest PlaceboIEM capsule difficulty Inability use mobile phone provide use clinical trial Any episodes acute rejection previous 3 month Presence cognitive impairment Active alcohol drug abuse History dysphagia , inflammatory bowel disease , gastrointestinal condition surgery modify normal luminal flow gastrointestinal tract ( e.g . Whipple procedure , bariatric surgery RouxenY ) Known allergy , include history skin reaction patch , could preclude safe participation study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Patient compliance</keyword>
	<keyword>ECMPS-IEM</keyword>
	<keyword>transplantation</keyword>
	<keyword>renal maintenance</keyword>
	<keyword>Proteus</keyword>
</DOC>